A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

Blood

Volumn 102, Issue 13, 2003, Pages 4277-4283

  Kell, William J ^b   Burnett, Alan K ^a   Chopra, Raj ^b   Yin, John A L ^b   Clark, Richard E ^b   Rohatiner, Ama ^b   Culligan, Dominic ^b   Hunter, Ann ^b   Prentice, Archie G ^b   Milligan, Donald W ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DIPHENHYDRAMINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; METHYLPREDNISOLONE; MITOXANTRONE; PARACETAMOL; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESEARCH; CLINICAL TRIAL; CONSOLIDATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; INDUCTION CHEMOTHERAPY; LIVER SINUSOID; LIVER TOXICITY; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUSOIDAL OBSTRUCTIVE SYNDROME; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 10744230708     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1620     Document Type: Article

References (28)

1. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML Trial (MRC AML 10). Blood. 1997;89:2311-2318.
2. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217-223.
3. Cassileth PA, Harrington DP, Appelbaum F, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
4. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90:2978-2986.
5. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-1717.
6. Burnett AK. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol. 2002;6:26-45.
7. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851.
8. Bradstock KF, Young GA, Lowenthal RM, Matthews JP. Intensive chemotherapy in induction and consolidation for de novo adult acute myeloid leukemia using sequential courses of high dose cytarabine, idarubicin, and etoposide; a randomized trial of the Australasian Leukaemia and Lymphoma Group (ALLG) [abstract]. Blood. 2001;98:462a.
9. Burnett AK, Goldstone AH, Stevens R, et al. Randomised comparison of addition of autologous bone-marrow transplantation in intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 Trial. Lancet. 1998;351:700-708.
10. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 Trial. Br J Haematol. 2002;118:385-400.
11. Lee MD, Dunne TM, Chang CC, Morton GO, Borders DB. Calicheamicins, a novel family of antitumour antibiotics, 1: chemistry and partial characterization of II. J Am Chem Soc. 1987;109:3464-3466.
12. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
13. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
14. Larson RA, Boogaerts MA, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-1636.
15. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;15:406-413.
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, March 31, 2003.
17. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27-41.
18. Green S, Benedetti J, Crowley J. Clinical Trials in Oncology. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC, 2003.
19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML: 10 Trial. Blood. 1998;92:2322-2333.
20. Burnett AK, Goldstone AH, Milligan DW. Daunorubicin versus mitoxantrone as induction for AML in younger adults given intensive chemotherapy: preliminary results of MRC AML12 trial [abstract]. Br J Haematol. 1999;105(suppl 1):67a.
21. Dinndorf PA, Andrews RG, Benjamin D, et al. Expression of normal myeloid associated antigens by acute leukemia cells. Blood. 1986;67:1048-1053.
22. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res. 1998;4:1421-1428.
23. Caron PC, Scheinberg D. A. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leuk Lymphoma. 1993;11:1-6.
24. Beyer CF. In vitro cellular cytotoxicity of NAc-calicheamicin gamma (CL181,927), NAc-calicheamicin gamma DMH (CL181,538), NAc-calicheamicin gamma DMH AcBut acid (CL191,305), and hP67.6-NAc-calicheamicin gamma DMH AcBut conjugate (CL555,201). American Cyanamid Company 1994, MIRACL 26753.
25. + acute myeloid leukaemia (AML) [abstract]. Blood. 2002;100:336a.
26. De Angelo DJ, Schiffer C, Stone R, et al. Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daurorubicin in patients < 60 years old with untreated acute myeloid leukemia [abstract]. Blood. 2002;100:198a-199a.
27. Wadleigh M, Zahneth D, Richardson PG, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogenic stem cell transplantation. Blood, 2003;102:1578-1582.
28. Deangelo DJ, Liu D, Stone R, et al. Preliminary report of a phase 2 study of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin in patients < 60 years of age with de novo acute myeloid leukaemia [abstract]. J Clin Oncol 2003;22:578a.